Site icon Revoi.in

Coronavirus: AstraZeneca to release more data on jab trials in US

Vials in front of the AstraZeneca British biopharmaceutical company logo are seen in this creative photo taken on 18 November 2020. Pfizer and Biontech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as media reported on 18 November 2020. (Photo by STR/NurPhoto via Getty Images)

Social Share

New Delhi: The UK-based pharmaceutical company AstraZeneca on Tuesday late night announced that it will release more data within 48 hours on US trials of its Covid-19 vaccine.

AstraZeneca announced to release more information when the US National Institute of Allergy and Infectious Diseases (NIAID) said “Out-dated information may have been used to conclude that its vaccine was highly effective against Covid.”

The health officials of the US – raised concerns about the initial information disclosed.

AstraZeneca in its official statement said that “We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis.”

“We intend to issue results of the primary analysis within 48 hours,” it added.

The US health agency’s evaluation comes after AstraZeneca said on Monday that stage three US trials of the vaccine had shown it was 79 percent effective.  AstraZeneca vaccine was suspended by several European countries while the other side – Canada, Vaccine manufacturer, and the WHO panel said AstraZeneca vaccine is safe.

-Vinayak